^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

icaritin (SNG-162)

i
Other names: SNG-162, IC-162, SNG162
Company:
Shenogen Pharma
Drug class:
ER-α 36 modulator
15d
Icaritin enhances the antitumor efficacy of irinotecan by dual-targeting carboxylesterase 2 and p53 in vitro and in vivo. (PubMed, Biochem Pharmacol)
Molecular docking simulations demonstrated that the interation energy between CES2 and icaritin was significantly higher than that with cisplatin (a reported CES2 activator), which might suggest that CES2 has a higher affinity for icaritin than cisplatin. These findings have important clinical significance for reducing chemotherapy drug resistance in cancer patients. Abbreviations: CES2, Carboxylesterase 2; CRC, Colorectal cancer; CPT-11, Irinotecan; CYP3A, Cytochrome P450 3A; NR, Nuclear receptor; P53, Tumor protein p53; PPAR-α, Peroxisome proliferator-activated receptor α; PXR, Pregnane X receptor; SN-38, 7-Ethyl-10-hydroxycamptothecin; UGT1A1, UDP-glucuronosyltransferase 1A1.
Preclinical • Journal
|
UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
|
cisplatin • irinotecan • icaritin (SNG-162)
23d
Dose-Exposure Study of Icaritin Soft Capsules in Patients with Advanced Hepatocellular Carcinoma (ChiCTR2600117381)
P=N/A, N=24, Completed, Jiangsu Provincial People's HospitalnNanjing Tianyinshan Hospital; Jiangsu Provincial People's Hospital
New trial
|
icaritin (SNG-162)
26d
Tanshinone IIA&Icaritin -MPs regulated vascular normalization and restored tumor-infiltrating T lymphocyte function to boost anti-PD-1 therapy in melanoma lung metastasis. (PubMed, J Nanobiotechnology)
Combining TSA&ICT-MP with α-PD-1 achieved a 70.33% suppression rate of lung metastasis and prolonged survival in murine models. This approach offers a promising strategy to enhance the efficacy of melanoma immunotherapy.
Journal
|
ELTD1 (Adhesion G Protein-Coupled Receptor L4)
|
icaritin (SNG-162)
1m
New P2 trial
|
AFP elevation
|
5-fluorouracil • oxaliplatin • leucovorin calcium • icaritin (SNG-162)
2ms
Mechanism of icariin in inhibiting spermatogonium apoptosis induced by high-fat diet based on Akt/MDM2/p53 pathway and mitochondrial fusion (PubMed, Zhongguo Zhong Yao Za Zhi)
Considering the metabolism of icariin into icaritin in vivo, icaritin was selected for in vitro study. Furthermore, MK2206 upregulated the expression levels of cleaved caspase-3 and p-p53(Ser15), as well as the Bax/Bcl-2 ratio, and downregulated the expression levels of p-Akt(Ser473) and p-MDM2(Ser166). These findings suggest that icariin protects against high-fat diet-induced spermatogonium apoptosis potentially through regulation of Akt/MDM2/p53 signaling and promotion of mitochondrial fusion.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MFN2 (Mitofusin 2)
|
MK-2206 • icaritin (SNG-162)
3ms
Identification and validation of icaritin-associated prognostic genes in hepatocellular carcinoma through network pharmacology, bioinformatics analysis, and cellular experiments. (PubMed, Front Immunol)
In vitro validation confirmed that ICT suppresses HepG2 and Huh7 cells proliferation and migration in a dose-dependent manner, while molecular analyses demonstrated that ICT treatment significantly downregulates CA9, UCK2, and FABP5 expression and simultaneously upregulates CYP2C9, thereby supporting its role in modulating critical oncogenic pathways. Modulation of ICT-targeted genes was found to effectively suppress HCC progression, underscoring their potential value as prognostic biomarkers and ideal therapeutic targets for the treatment of HCC.
Journal
|
CA9 (Carbonic anhydrase 9) • CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • FABP5 (Fatty Acid Binding Protein 5)
|
icaritin (SNG-162)
3ms
A Multimodal Energy-Depletion Strategy for Cooperative Tumor Metabolism Regulation in Enhanced Cancer Therapy. (PubMed, Biomater Res)
Herein, this work introduces an Artesunate/Icaritin (ART/ICA) hybrid nanoplatform derived from herbal medicine that employs a multimodal energy depletion strategy for malignant tumor therapy...In vivo evaluations using various tumor models, including hepatocellular carcinoma transgenic mouse models, confirmed significantly enhanced antitumor efficacy, while subcutaneous tumor models showed a tumor inhibition rate exceeding 97%, far surpassing the effects of ART or ICA alone. Furthermore, flow cytometry analyses also confirmed that this strategy modulated the tumor microenvironment by enhancing the infiltration of cytotoxic CD8+ T cells and promoting dendritic cell maturation, while the incorporation of a CD47-targeting nanobody further strengthened immune activation and contributed to improved antitumor efficacy.
Journal
|
CD8 (cluster of differentiation 8)
|
icaritin (SNG-162)
4ms
Novel senescence inducer ICA-11c, a derivative of icaritin, YAP-dependently suppresses hepatocellular carcinoma cells. (PubMed, Chem Biol Interact)
Our findings not only show that ICA-11c served as a potential YAP regulator for the treatment of hepatocellular carcinoma, but also explore the relationship between YAP and cellular senescence. This study suggests that ICA-11c may be a potential novel inducer of cellular senescence in hepatocellular carcinoma cells.
Journal
|
CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
icaritin (SNG-162)
4ms
New P2 trial
|
Avastin (bevacizumab) • Tyvyt (sintilimab) • icaritin (SNG-162)
5ms
Enrollment open
|
icaritin (SNG-162)
5ms
Elucidating the Pharmacological Basis of Xianling Cifang Granules Against Breast Cancer. A Metabolomic Profiling Study. (PubMed, Drug Des Devel Ther)
Icaritin (a metabolite derived from Epimedium brevicornu Maxim) was identified as a pivotal constituent due to its high bioavailability and established anti-BC activity, specifically inducing redox-mediated apoptosis via the SIRT6/NF-κB pathway and modulating the immunosuppressive microenvironment in triple-negative breast cancer (TNBC)...These findings provide robust pharmacological evidence supporting the clinical application of XLCF against BC and demonstrate the value of combining metabolomics with target prediction for Traditional Chinese Medicine (TCM) research. Experimental validation of the identified targets is warranted.
Journal • Metabolomic study
|
SIRT6 (Sirtuin 6)
|
icaritin (SNG-162)
9ms
Pharmacokinetic Study of Icaritin Soft Capsules in Healthy Chinese Subjects (ChiCTR2500101716)
P1, N=10, Not yet recruiting, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Shuguang Hospital Affiliated to Shanghai University of Traditiona
New P1 trial
|
icaritin (SNG-162)